Immunovant

IMVT · NASDAQ

$28.59+$0.97 (+3.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $27.62

IMVT analyst rating

BuyConsensus of 8 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy6
Hold2
Underperform0
Sell0

12-month price target · 18 analysts

Average $49.78 (+74.1% upside)

Low: $30.30
Now: $28.59
High: $69.30

Upgrades and downgrades

The latest rating actions, newest first

IMVT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Aug 4, 2026	Maintains	Overweight	$47.00 → $50.00	40%
Citigroup	Jun 30, 2026	Maintains	Buy	$57.00 → $61.00	36%
Guggenheim	May 26, 2026	Maintains	Buy	$44.00 → $62.00	49%
Truist Securities	May 22, 2026	Maintains	Hold	$23.00 → $30.00	36%
B of A Securities	May 21, 2026	Maintains	Buy	$32.00 → $43.00	56%
HC Wainwright & Co.	May 21, 2026	Maintains	Buy	$35.00 → $40.00	50%
Goldman Sachs	Apr 15, 2026	Maintains	Neutral	$29.00 → $32.00	53%
HC Wainwright & Co.	Feb 10, 2026	Maintains	Buy	$35.00	50%
Guggenheim	Feb 9, 2026	Maintains	Buy	$41.00 → $44.00	49%
Truist Securities	Jan 8, 2026	Maintains	Hold	$16.00 → $22.00	36%

The case for and against

Updated Aug 1, 2026

Bull case

Immunovant is a promising company with a potential first-in-class FcRn inhibitor in Difficult-to-Treat RA. The company has a strong pipeline with multiple upcoming catalysts, including potential registrational trial data for IMVT-1402 in GD and MG. The company's current financial situation is solid with sufficient funding to support ongoing operations and potential commercial launch of IMVT-1402. Risks to achieving the price target include regulatory and clinical, COVID-19 impact, and competition in the market.

Bear case

Immunovant is facing potential risks in their upcoming Phase 2 study, as the high efficacy in Period 1 may make Period 2 statistically riskier, potentially hindering their chances of gaining FDA approval. Additionally, the ongoing period 2 study, combined with one more pivotal trial, may not be sufficient for registration, risking delays in bringing their potential treatment to market. With a lack of other significant sources of revenue, the success of their lead product is crucial to the company's financial stability and future growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.